U.S. Consumer Finance Stock News

NasdaqGM:RDNT
NasdaqGM:RDNTHealthcare

RadNet (RDNT) Q1 Loss Widens Again And Tests Bullish AI Margin Narrative

RadNet Q1 2026 earnings: revenue expands while margins stay under pressure RadNet (RDNT) opened 2026 with Q1 revenue of US$575.6 million and a basic EPS loss of US$0.43, as the stock trades around US$58.19. The company has seen revenue move from US$471.4 million in Q1 2025 to US$575.6 million in Q1 2026, while quarterly EPS has shifted from a loss of US$0.51 to a loss of US$0.43 over the same period. This sets up a results season where investors are watching how quickly revenue scale can...
NasdaqGS:STRA
NasdaqGS:STRAConsumer Services

Does AI-Driven Efficiency Amid Softer Enrollment Change The Bull Case For Strategic Education (STRA)?

In its latest quarter, Strategic Education reported mixed results as weaker U.S. enrollment contrasted with improved profitability driven by cost controls and AI-related efficiencies. An interesting takeaway is how AI-enabled operational gains and expense discipline supported earnings even as core enrollment trends showed signs of strain. Next, we'll examine how these AI-driven efficiency gains, alongside softer enrollment, may reshape the existing investment narrative for Strategic...
NYSE:PPL
NYSE:PPLElectric Utilities

PPL’s Nuclear Feasibility Push Adds New Angle To Valuation Debate

PPL (NYSE:PPL) has partnered with X-energy Inc. to explore deployment of Xe-100 small modular nuclear reactors through its Louisville Gas and Electric Company and Kentucky Utilities subsidiaries. The collaboration aligns with Kentucky’s new $75 million grant program that supports nuclear readiness and feasibility studies across the state. The effort focuses on assessing how small modular nuclear reactors could fit into PPL’s long term generation mix and support grid reliability and clean...
NYSE:ONON
NYSE:ONONLuxury

Lazard And 2 Stocks That May Be Trading Below Their Estimated Value

Over the last 7 days, the United States market has risen by 2.2%, contributing to a significant 31% increase over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for growth and diversification.
NYSE:RYAN
NYSE:RYANInsurance

Clover Health Investments And 2 Other Insider Picks For Growth

Over the last 7 days, the United States market has risen by 2.2%, contributing to a substantial 31% climb over the past year, with earnings expected to grow by 17% annually. In such an environment, stocks with high insider ownership can be appealing as they often indicate confidence from those closest to the company’s operations and potential for growth, making them noteworthy considerations for investors seeking opportunities in this thriving market.
NasdaqGS:OPK
NasdaqGS:OPKHealthcare

Spotlight On Promising Penny Stocks For May 2026

Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.
NasdaqGS:MCBS
NasdaqGS:MCBSBanks

US Market's 3 Undiscovered Gems with Promising Potential

Over the last 7 days, the United States market has risen by 2.2%, contributing to a notable 31% increase over the past year, with earnings expected to grow by 17% annually in the coming years. In this thriving environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering hidden opportunities within the market's landscape.
NasdaqGS:ARTN.A
NasdaqGS:ARTN.AWater Utilities

3 Prominent Dividend Stocks To Consider For Your Portfolio

Over the last 7 days, the United States market has risen by 2.2%, and over the past 12 months, it has seen a substantial increase of 31%, with earnings forecasted to grow by 17% annually. In this context of robust growth, identifying dividend stocks that offer reliable income along with potential capital appreciation can be an effective strategy for enhancing portfolio stability and returns.
NasdaqCM:ONDS
NasdaqCM:ONDSCommunications

Is It Too Late To Consider Ondas (ONDS) After A 9x Three Year Surge?

Wondering whether Ondas stock still offers value after a sharp run up, or if most of the opportunity is already reflected in the price. The stock closed at US$9.06, with the share price down 6.9% over the last week and down 0.8% over the past month, despite a very large return over the last year and a return of around 9x over three years. That kind of move has put Ondas firmly on many investors' radars, prompting closer attention on what is driving sentiment and how sustainable it might be...
NasdaqGS:AMAT
NasdaqGS:AMATSemiconductor

Applied Materials TSMC AI Chip Partnership Meets Stretched Valuation Concerns

Applied Materials (NasdaqGS:AMAT) and TSMC announced a new co-innovation partnership focused on advanced semiconductor technologies for AI. The collaboration targets faster development and commercialization of next generation AI hardware process technologies. This news adds a fresh chapter to the Applied Materials story beyond prior coverage of its NEXX acquisition and advanced packaging efforts. Applied Materials sits at the heart of chip manufacturing equipment, and this new partnership...
NYSE:PLNT
NYSE:PLNTHospitality

A Look At Planet Fitness (PLNT) Valuation After Guidance Cut And Paused Black Card Price Hike

Planet Fitness (PLNT) just reported Q1 2026 results that beat expectations on revenue and earnings. However, the stock dropped sharply after management cut full year growth guidance and paused a planned Black Card price increase. See our latest analysis for Planet Fitness. The sharp guidance cut and paused pricing move have reset expectations, with the 7 day share price return down 27.51% and the 1 year total shareholder return down 51.31%. This signals fading momentum despite the latest...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is It Too Late To Consider EyePoint (EYPT) After A 133% One-Year Surge?

Wondering whether EyePoint at US$13.66 still offers value after a big run, or whether most of the opportunity is already priced in. The stock is up 133.5% over the past year and 127.7% over three years, even though it has fallen 1.4% over the last week, 3.7% over the past month and 21.9% year to date. Recent market attention on EyePoint has focused on its position within the US pharmaceuticals and biotech space and how investors are reassessing risk across smaller healthcare stocks...
NYSE:GEV
NYSE:GEVElectrical

GE Vernova’s Dogger Bank Role Grows As Valuation Questions Persist

GE Vernova (NYSE:GEV) has selected Scotland’s Maraen Port of Nigg as the marshalling hub for turbine components for the Dogger Bank Wind Farm phases B and C. The port will handle logistics and staging activity for upcoming project phases, supporting one of the world's largest offshore wind developments. This appointment adds another large offshore wind project to GE Vernova’s execution pipeline in the European renewables supply chain. For investors following NYSE:GEV, this move underlines...
NYSE:BR
NYSE:BRProfessional Services

Broadridge Extends LTX Reach As Major Banks Deepen Bond Trading Ties

Broadridge Financial Solutions (NYSE:BR) added Goldman Sachs, J.P. Morgan, TD Securities, Morgan Stanley, and Bank of America as fully integrated liquidity providers on its LTX bond trading platform. J.P. Morgan and TD Securities joined the LTX board as part of the expansion, deepening their involvement with the AI powered electronic bond trading venue. The new relationships increase the institutional presence on LTX and broaden its reach across the corporate bond market. For you as an...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?

If you are wondering whether Amylyx Pharmaceuticals at US$14.73 is still offering value after a strong run, it helps to step back and look at what the price is really reflecting. The stock is up 29.0% year to date and 220.2% over the past year, even though it has fallen about 10.5% over the past week and 10.0% over the past month. These moves can change how you think about both opportunity and risk. Across financial media and industry commentary, recent attention has focused on Amylyx as a...
NYSE:MFA
NYSE:MFAMortgage REITs

Will MFA’s Q1 Net Loss and Buybacks Reshape MFA Financial's (MFA) Capital Allocation Narrative?

MFA Financial, Inc. reported first-quarter 2026 results showing a net loss of US$984,000 and basic and diluted loss per share of US$0.11 from continuing operations, while also completing a buyback of 500,660 shares for US$5.01 million under its February 18, 2026 repurchase authorization. Management linked the loss to higher rates, wider mortgage spreads, and geopolitical tensions, while simultaneously pursuing expense reduction, portfolio growth and loan resolutions, underscoring a tension...